e-therapeutics plc Financials

Market Capitalization £65.7 Million as of Jan. 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE	-610.39
Forward PE
Price to Sales TTM	£167.57
Price to Book MRQ	£200.00
Enterprise to Revenue	88.29
Enterprise to EBITDA	-2.39

Financial Reports as of Jul. 31, 2023

Financials

Fiscal Year Ends	2023-01-31
Most Recent Quarter	2023-07-31
Profit Margin	100.00%
Operating Margin	-4356.25%
Return on Assets TTM	-29.10%
Return on Equity TTM	-38.75%

Income Statement

Revenue TTM	£340,000
Revenue per Share TTM	£0.00
Quarterly Revenue Growth	-45.80%
Gross Profit TTM	£475,000
EBITDA	£-12,558,000
Net Income to Common TTM	£-10,056,000
Diluted EPS TTM	£-0.02
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	£24,845,000
Total Cash per Share MRQ	£0.04
Total Debt MRQ	£
Total Debt to Equity MRQ	0.33
Current Ratio MRQ	22.20
Book Value per Share MRQ	£0.05

Cash Flow

Operating Cash Flow TTM	£-10,154,000
Levered Free Cash Flow TTM	£-7,640,125

ETX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	584,334,976
Float Shares	245,640,551
Avg 10 Volume	2,203,287
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	59.44%
% Held by Institutions	26.54%

Stock Price Summary

Beta	0.43
Fifty Two Week Low	£0.09
Fifty Two Week High	£24.00
Fifty Two Week Change	-38.56%
Day 50 MA	£11.57
Day 200 MA	£12.60

Dividends and Splits

Forward Annual Dividend Rate	£
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	£0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date